Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)

NCT00040534 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Farnesyl Protein Transferase Inhibitor

Sponsor

Merck Sharp & Dohme LLC